Refine Search

Search Results -

Terms	Documents
$carnitine adj15 liposome	15

Database: US Pre-Grant Publication Full-Text Database; US Patents Full-Text Database; US OCR Full-Text Database; EPO Abstracts Database; JPO Abstracts Database; Derwent World Patents Index; IBM Technical Disclosure Bulletins

Search: L8

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Thursday, January 11, 2007 **Purge Queries** Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L8	$carnitine adj15 liposome	15	L8
L7	L6 and 424/450.ccls.	13	L7
L6	$carnitine same liposome	430	L6
L5	L4 and liposome	2	L5
L4	acetyl$carnitine and 424/450.ccls.	4	L4
L3	acetyl$carnitine	561	L3
L2	alkyl$carnitine	0	L2
L1	alkyl$carnitine and 424/450.ccls.	0	L1

END OF SEARCH HISTORY

L5: Entry 2 of 2 File: USPT Dec 25, 2001

DOCUMENT-IDENTIFIER: US 6333057 B1
TITLE: Composition and method for topical treatment of androgenic alopecia

Brief Summary Text (25):
The term "acetyl carnitine" refers to various forms of acetyl carnitine, including but not limited to, D,L-carnitine, and acetyl-L-carnitine hydrochloride which is usually employed in a 1% to 5% solution. Acetyl carnitine (PCAA, Houston, Tex.) is thought to decrease in senescence and down regulation. Although not wanting to be bound by this statement, it is believed that the decrease in acetyl carnitine compromises the transport of fatty acids from the cytosol into the inner mitochondrial membrane of the mitochondria, thereby impairing the physiological function of the follicle, perhaps through effects on fatty acid oxidation and ATP production. Acetyl carnitine is believed to improve fatty acid metabolism by stimulation of cardiolipin which affects the activity of the inner mitochondrial membrane, affecting its permeability and function for proton transport. Acetyl carnitine is also believed to synergize with co-enzyme Q in the revitalization of senescent hair follicles.

Brief Summary Text (29):
"Topical" application is used to mean local administration of the composition and its various embodiments, for example, in the treatment of alopecia. The composition according to the present invention can be in the form of solutions, lotions, salves, creams, ointments, liposomes, sprays, gels, roller sticks or any other method using micelles and pharmaceutically acceptable penetration enhancers. In one embodiment, the composition may be applied to the scalp at bedtime and again after showering in the morning for a total of two applications per day.

Brief Summary Text (36):
The present invention optionally includes lecithin (20% -98%) dissolved with isopropyl palmitate or other solvents in combination with an approximately 10% -20% solution of PLURONIC F-127 (BASF, Parsippany, N.J.), otherwise known as poloxamer 407, in a ratio of approximately 1:3 to 1:4. This ratio may be varied by one of ordinary skill in the art. Other PLURONICS may be used in the present invention. It is to be understood that the soy lecithin of the present invention is a preferred lecithin source and may be dissolved in isopropyl palmitate to achieve a final concentration in the composition of from approximately 20% -98%, with a more preferred final concentration of from approximately 20%-40%. Lecithins may optionally be derived from eggs, and organs such as heart, brain, and liver, and used at concentrations of approximately 20%-99%, with more preferred final concentrations of from approximately 20%-40%. The composition according to the present invention can be in the form of lotions, salves, creams, ointments, liposomes, sprays, micelles, or gels. The desired form is lotions, ointments and salves. Liposomes are described in detail by Oleniacz in U.S. Pat. No. 3,957,971, the entirety of which is hereby incorporated by reference.

Current US Cross Reference Classification (1):
424/450

Previous Doc Next Doc Go to Doc#

First Hit Previous Doc Next Doc Go to Doc#

Generate Collection Print

L7: Entry 4 of 13 File: PGPB Apr 4, 2002

DOCUMENT-IDENTIFIER: US 20020039595 A1
TITLE: ORAL LIPOSOMAL DELIVERY SYSTEM

Current US Classification, US Primary Class/Subclass:
424/450

Detail Description Paragraph:
[0028] Components are commingled and liposomes are made using the injection method (Lasic, D., Liposomes, Elsevier, 88-90, 1993). When liposome mixture cooled down 0.7 ml was drawn into a 1 ml insulin syringe and injected into the open-end of a soft gelatin capsule then sealed with tweezers. The resulting one gram capsule contains 735 mg of L-Carnitine. Filling of gel caps on a large scale is best with the rotary die method or others such as the Norton capsule machine.

CLAIMS:

8. The liposome-capsule dosage unit of claim 1 wherein the biologically active material is L-Carnitine.

Previous Doc Next Doc Go to Doc#

First Hit Fwd Refs Previous Doc Next Doc Go to Doc#

Generate Collection Print

L7: Entry 7 of 13 File: USPT Apr 27, 2004

DOCUMENT-IDENTIFIER: US 6726924 B2
TITLE: Oral liposomal delivery system

Detailed Description Text (9):
Components are commingled and liposomes are made using the injection method (Lasic, D., Liposomes, Elsevier, 88-90, 1993). When liposome mixture cooled down 0.7 ml was drawn into a 1 ml insulin syringe and injected into the open-end of a soft gelatin capsule then sealed with tweezers. The resulting one gram capsule contains 735 mg of L-Carnitine. Filling of gel caps on a large scale is best with the rotary die method or others such as the Norton capsule machine.

Current US Original Classification (1):
424/450

Previous Doc Next Doc Go to Doc#

First Hit Previous Doc Next Doc Go to Doc#

Generate Collection Print

L8: Entry 12 of 15 File: DWPI Nov 1, 2001

DERWENT-ACC-NO: 2002-264987
DERWENT-WEEK: 200231

TITLE: Cosmetic composition for improving skin

INVENTOR: CHO, B G; KIM, B J ; LEE, S J

PATENT-ASSIGNEE: COREANA COSMETICS CO LTD (COREN)

PRIORITY-DATA: 2000KR-0016922 (March 31, 2000)

Search Selected Search ALL Clear

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
KR 2001094548 A	November 1, 2001		000	A61K007/00

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
KR2001094548A	March 31, 2000	2000KR-0016922	

INT-CL (IPC): A61K 7/00

ABSTRACTED-PUB-NO: KR2001094548A
BASIC-ABSTRACT:

NOVELTY - Provided is a cosmetic composition containing esculin, L-carnitine, caffeine, and ruscogenin to improve sagging face, waist and breast, skin texture and obesity caused by lipid accumulation.

DETAILED DESCRIPTION - The cosmetic composition contains 0.05-20.0, preferably 0.1-10 wt.% of slimming liposome based on the total weight of cosmetic composition. The slimming liposome includes 0.001-30., preferably 0.01-1.0 wt.% of esculin, 0.001-3.0, preferably 0.01-1.0 wt.% of L-carnitine, 0.001-3.0, preferably 0.0-1.0 wt.% of caffeine and 0.001-5.0, preferably 0.05-2.0 wt.% of ruscogenin which are stabilized by liposome technique. The slimming liposome is pseudo liposome having a particle size less than 300 nm and manufactured by using phospholipid and carrier oil, such as collagen and GAGs.

ABSTRACTED-PUB-NO: KR2001094548A
EQUIVALENT-ABSTRACTS:

CHOSEN-DRAWING: Dwg.0/0

DERWENT-CLASS: D21 E19

CPI-CODES: D08-B09A; E01; E06-A01; E06-D09; E10-A22D;

Previous Doc Next Doc Go to Doc#

Hit List

First Hit | Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 2 of 2 returned.

☐ 1. Document ID: US 20030068365 A1

L5: Entry 1 of 2 File: PGPB Apr 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030068365
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030068365 A1

TITLE: Compositions and methods for administration of active agents using liposome beads

PUBLICATION-DATE: April 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY
Suvanprakorn, Pichit	Bangkok	FL	TH
Ploysangam, Tanusin	Bangkok		TH
Tanasugarn, Lerson	Bangkok		TH
Chandrkrachang, Suwalee	Bangkok		TH
Zaias, Nardo	Miami Beach		US

US-CL-CURRENT: 424/450; 424/725

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw De

☐ 2. Document ID: US 6333057 B1

L5: Entry 2 of 2 File: USPT Dec 25, 2001

US-PAT-NO: 6333057
DOCUMENT-IDENTIFIER: US 6333057 B1

TITLE: Composition and method for topical treatment of androgenic alopecia

DATE-ISSUED: December 25, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Crandall; Wilson T.	Ft. Defiance	VA	24437	

US-CL-CURRENT: 424/727; 424/450, 424/484, 424/489, 424/70.1, 514/170, 514/690, 514/78, 514/880, 514/930, 514/944, 514/946, 514/951, 514/959, 514/961

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw D

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
L4 and liposome	2

Display Format: - Change Format

Previous Page Next Page Go to Doc#

Refine Search

Search Results -

Terms	Documents
$carnitine adj5 vascular	36

Database:
US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search: L4

Refine Search | Recall Text | Clear | Interrupt

Search History

DATE: Thursday, January 11, 2007 **Purge Queries** Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR			
L4	$carnitine adj5 vascular	36	L4
L3	L2 and liposome	72	L3
L2	$carnitine same vascular	220	L2
L1	$carnitine same liposome same vascular	0	L1

END OF SEARCH HISTORY

L4: Entry 10 of 36 File: USPT Nov 4, 2003

DOCUMENT-IDENTIFIER: US 6641849 B1
TITLE: Composition for the prevention and/or treatment of circulatory disorders, comprising derivatives of L-carnitine and extracts of ginkgo biloba

Brief Summary Text (37):
A series of tests was conducted using the method described by Young (Young J. N., Prostaglandins 30:545, 1985) and by Myers (Myers H., Br. J. Pharmacol., 79:595, 1983) in order to assess whether Ginkgo biloba extracts (whose anti-PAF activity is known) protect animals injected with PAF against death and whether the carnitines (particularly propionyl L-carnitine, whose vascular regulatory activity is known) are capable of increasing the protective effect against PAF.

L4: Entry 11 of 36 File: USPT Jun 3, 2003

DOCUMENT-IDENTIFIER: US 6573299 B1
TITLE: Method and compositions for treatment of the aging eye

Brief Summary Text (47):
The use of NOS inhibitors is well known in the art. Cavazza, U.S. Pat. Nos. 5,432,199 and 5,747,536, discloses the use of L-carnitine and resveratrol to treat peripheral vascular diseases and peripheral diabetic neuropathy or acetyl D-camitine to treat glaucoma. Dawson et al, U.S. Pat. No. 5,266,594, discloses a method of preventing or treating glutamate neurotoxicity with a NOS inhibitor capable of penetrating the blood brain barrier. Ahluwalia et al, U.S. Pat. No. 5,468,476, discloses a method of reducing hair growth with a NOS inhibitor. Wahl et al, U.S. Pat. No. 5,449,688, discloses a method for treating chronic inflammatory conditions by parenterally or intravenously administering a NOS inhibitor. Stamler et al, U.S. Pat. No. 5,545,614, discloses a method for stimulating skeletal muscle contractions with a NOS inhibitor. Moncada et al, U.S. Pat. No. 5,585,402, discloses a method for inhibiting tissue damage by using a NOS inhibitor to decrease NO production in vascular endothelial cells. Dunn et al, U.S. Pat. No. 5,665,757, discloses a method for treating anxiety using a NOS inhibitor. Mjalli et al, U.S. Pat. No. 5,723,451, discloses a method for inhibiting NOS using one of eleven formulations. None of the above cited patents teach or suggest the use of the composition and method outlined in the present invention.

First Hit Fwd Refs Previous Doc Next Doc Go to Doc#

Generate Collection Print

L4: Entry 26 of 36 File: USPT Nov 6, 1990

DOCUMENT-IDENTIFIER: US 4968719 A
TITLE: Method for treating vascular disease

Abstract Text (1):
L-carnitine is effective for the treatment of peripheral vascular diseases, such as intermittent claudication. Administration of L-carnitine to patients suffering from intermittent claudication results in a significant increase in the distance the patients can walk before experiencing claudication.

Detailed Description Text (33):
Table 5 shows changes in total, free, and esterified carnitine concentrations induced by L-carnitine in patients with peripheral vascular disease. Normal values were obtained from six normal subjects matched to the patients with peripheral arterial disease with respect to age and sex, chosen from a group of 46 normal individual previously studied.

Previous Doc Next Doc Go to Doc#

L4: Entry 31 of 36 File: USPT Aug 10, 1982

DOCUMENT-IDENTIFIER: US 4343816 A
TITLE: Pharmaceutical composition comprising an acyl-carnitine, for treating peripheral vascular diseases